IPP Bureau

Pfizer sets up global drug development centre in Chennai
Pfizer sets up global drug development centre in Chennai

By IPP Bureau - May 04, 2022

The facility is among 12 centres established worldwide, and the first in Asia

Sona Group partners with Mycelium Biotechnology for R&D in Salem
Sona Group partners with Mycelium Biotechnology for R&D in Salem

By IPP Bureau - May 02, 2022

As a global mushroom biotechnology group, Mycelium Biotechnology is engaged in mushroom growing, global distribution and offering biotechnology and nutraceutical solutions through global partners

Xcardia announces first-in-human use of its new Xtractor device
Xcardia announces first-in-human use of its new Xtractor device

By IPP Bureau - May 02, 2022

The announcement follows FDA 510(k) clearance of device

NORD announces over US $ 100,000 in grant funding available for rare disease research
NORD announces over US $ 100,000 in grant funding available for rare disease research

By IPP Bureau - May 02, 2022

Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program

CIVCO Radiotherapy to Unveil TotalRT All in One Solution at ESTRO 2022
CIVCO Radiotherapy to Unveil TotalRT All in One Solution at ESTRO 2022

By IPP Bureau - May 02, 2022

CIVCO RT will also display its recent innovations focusing on improving patient comfort and outcomes

World’s first AI software for detecting pancreatic disease on the horizon
World’s first AI software for detecting pancreatic disease on the horizon

By IPP Bureau - May 02, 2022

As an industrial partner of the IHU, the Medi-Globe Group is thus further expanding its role as an innovation leader in minimally invasive diagnostics and therapies

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical
Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical

By IPP Bureau - May 02, 2022

Avacc 3 has significant advantages over existing whooping cough vaccines

StanPlus appoints Gurjit Singh as COO and Founding Member
StanPlus appoints Gurjit Singh as COO and Founding Member

By IPP Bureau - May 02, 2022

He will be leading the business, operations, P&L, and growth strategy for StanPlus

USFDA concludes inspection of Shilpa Medicare with four observations
USFDA concludes inspection of Shilpa Medicare with four observations

By IPP Bureau - May 02, 2022

The inspection was triggered by Shilpa's submission of applications for four ANDA's to seek approval to use this site as an alternate testing laboratory

Physicians foresee an Alzheimer's Disease treatment revolution supported by advanced testing tools
Physicians foresee an Alzheimer's Disease treatment revolution supported by advanced testing tools

By IPP Bureau - May 02, 2022

Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education

NHA enlists Pristyn Care as health tech partner for Ayushman Bharat Digital Mission
NHA enlists Pristyn Care as health tech partner for Ayushman Bharat Digital Mission

By IPP Bureau - May 02, 2022

ABDM is a critical integration that leverages an open, interoperable, standards-based digital system that is secure, and maintains confidentiality and privacy of health-related personal information

Dr. Mansukh Mandaviya to chair a three-day health meet at Kevadia in Gujarat
Dr. Mansukh Mandaviya to chair a three-day health meet at Kevadia in Gujarat

By IPP Bureau - May 02, 2022

State Ministers of Health and Medical Education to Participate in the meeting from 5th to 7th May

Sage Therapeutics and Biogen initiate rolling submission of New Drug Application for Zuranolone
Sage Therapeutics and Biogen initiate rolling submission of New Drug Application for Zuranolone

By IPP Bureau - May 02, 2022

The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023

USFDA approves Rinvoq as an oral treatment for ankylosing spondylitis
USFDA approves Rinvoq as an oral treatment for ankylosing spondylitis

By IPP Bureau - May 01, 2022

The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases

Moderna finalizes plan for long-term strategic partnership with Canada
Moderna finalizes plan for long-term strategic partnership with Canada

By IPP Bureau - May 01, 2022

Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually

Latest Stories

Interviews

Packaging